Inspire Medical wins new CPT codes for its Inspire V device

Inspire Medical Systems has secured approval from the American Medical Association's CPT Editorial Panel for a new set of Category I procedural codes that specifically describe the company's Inspire V hypoglossal nerve stimulation system. The codes are scheduled to take effect on 1 January 2028, setting in motion a reimbursement pathway that the Minneapolis-based company says will reduce administrative friction for hospitals and physicians treating patients with obstructive sleep apnea (OSA).

The new codes cover the implantation of a single-lead implantable pulse generator, the architecture used in the recently launched Inspire V system. Inspire said the application attracted broad support from specialty societies including the American Academy of Otolaryngology-Head and Neck Surgery, the American Academy of Sleep Medicine, and the International Surgical Sleep Society.

Reimbursement timeline

With Category I codes now approved, the Centers for Medicare and Medicaid Services will begin its standard valuation process. CMS is expected to request a review from the AMA's Relative Value Scale Update Committee, which will assess physician time, complexity, practice expenses, and liability insurance costs. Specialty societies such as the AAO-HNS may survey members and submit recommendations to the RUC as part of that process. Inspire anticipates CMS will publish proposed valuations in July 2027, with final valuations confirmed in November 2027, one month ahead of the codes coming into force.

Tim Herbert, chairman and chief executive of Inspire Medical Systems, said the dedicated codes will "create a clearer, more consistent path for coding and reimbursement" and that the company expects the change to support continued growth in patient access. The company reports more than 140,000 patients treated and over a decade of clinical experience with its neurostimulation platform.

Market context

Dedicated Category I CPT codes carry meaningful commercial weight. The shift from temporary or miscellaneous codes to permanent Category I status typically simplifies billing workflows and reduces claim denials, both of which can accelerate device adoption in the hospital outpatient setting. For a company like Inspire, which competes in a segment that also faces competition from continuous positive airway pressure therapy and, increasingly, from pharmaceutical candidates targeting the upper airway musculature, removing reimbursement friction is a credible lever for volume growth.

The broader hypoglossal nerve stimulation market remains relatively concentrated. Inspire holds FDA, EU MDR, and PDMA approval for its therapy, positioning it as the incumbent with the longest clinical track record in the space. Other medtech players have explored upper-airway neurostimulation, but none yet match Inspire's market footprint. The January 2028 effective date gives CMS, payers, and hospital coding departments roughly fifteen months to prepare, which is broadly consistent with standard implementation timelines for major procedural code changes.

Investors will watch the CMS proposed rule in mid-2027 closely. The relative value assigned to the new codes will determine Medicare reimbursement rates and, indirectly, influence commercial payer negotiations. An unfavourable valuation could offset some of the administrative benefits the code approval delivers.